JP2004528002A - 分泌分子および輸送分子 - Google Patents

Info

Publication number

JP2004528002A

JP2004528002A JP2002507862A JP2002507862A JP2004528002A JP 2004528002 A JP2004528002 A JP 2004528002A JP 2002507862 A JP2002507862 A JP 2002507862A JP 2002507862 A JP2002507862 A JP 2002507862A JP 2004528002 A JP2004528002 A JP 2004528002A

Authority

JP

Japan

Prior art keywords

polypeptide

polynucleotide

seq

sat

antibody

Prior art date

2000-06-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 230000003248 secreting effect Effects 0.000 title description 11
• 108091033319 polynucleotide Proteins 0.000 claims abstract description 282
• 102000040430 polynucleotide Human genes 0.000 claims abstract description 282
• 239000002157 polynucleotide Substances 0.000 claims abstract description 282
• 238000000034 method Methods 0.000 claims abstract description 212
• 230000014509 gene expression Effects 0.000 claims abstract description 124
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 82
• 201000010099 disease Diseases 0.000 claims abstract description 62
• 239000000556 agonist Substances 0.000 claims abstract description 18
• 239000005557 antagonist Substances 0.000 claims abstract description 17
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 239
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 222
• 229920001184 polypeptide Polymers 0.000 claims description 213
• 210000004027 cell Anatomy 0.000 claims description 172
• 239000012634 fragment Substances 0.000 claims description 134
• 150000001875 compounds Chemical class 0.000 claims description 124
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 101
• 239000000523 sample Substances 0.000 claims description 98
• 150000007523 nucleic acids Chemical class 0.000 claims description 81
• 238000009396 hybridization Methods 0.000 claims description 75
• 125000003729 nucleotide group Chemical group 0.000 claims description 70
• 239000002773 nucleotide Substances 0.000 claims description 69
• 230000000694 effects Effects 0.000 claims description 57
• 238000012360 testing method Methods 0.000 claims description 56
• 230000027455 binding Effects 0.000 claims description 52
• 102000039446 nucleic acids Human genes 0.000 claims description 43
• 108020004707 nucleic acids Proteins 0.000 claims description 43
• 230000000295 complement effect Effects 0.000 claims description 40
• 238000011282 treatment Methods 0.000 claims description 39
• 239000000203 mixture Substances 0.000 claims description 32
• 239000012472 biological sample Substances 0.000 claims description 30
• 238000012216 screening Methods 0.000 claims description 30
• 230000002068 genetic effect Effects 0.000 claims description 23
• 230000002163 immunogen Effects 0.000 claims description 20
• 230000008569 process Effects 0.000 claims description 20
• 241001465754 Metazoa Species 0.000 claims description 19
• 238000004519 manufacturing process Methods 0.000 claims description 16
• 231100000419 toxicity Toxicity 0.000 claims description 14
• 230000001988 toxicity Effects 0.000 claims description 14
• 230000008859 change Effects 0.000 claims description 11
• 230000002829 reductive effect Effects 0.000 claims description 10
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
• 230000009870 specific binding Effects 0.000 claims description 8
• 230000002018 overexpression Effects 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 108060003951 Immunoglobulin Proteins 0.000 claims description 4
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
• 238000012408 PCR amplification Methods 0.000 claims description 4
• 210000004408 hybridoma Anatomy 0.000 claims description 4
• 230000003053 immunization Effects 0.000 claims description 4
• 102000018358 immunoglobulin Human genes 0.000 claims description 4
• 238000012258 culturing Methods 0.000 claims description 3
• 230000005875 antibody response Effects 0.000 claims 2
• 210000000628 antibody-producing cell Anatomy 0.000 claims 2
• 238000002405 diagnostic procedure Methods 0.000 claims 1
• 241000282414 Homo sapiens Species 0.000 abstract description 31
• 239000013604 expression vector Substances 0.000 abstract description 24
• 230000002159 abnormal effect Effects 0.000 abstract description 9
• AGGIJOLULBJGTQ-UHFFFAOYSA-N sulfoacetic acid Chemical compound OC(=O)CS(O)(=O)=O AGGIJOLULBJGTQ-UHFFFAOYSA-N 0.000 description 261
• 108090000623 proteins and genes Proteins 0.000 description 220
• 102000004169 proteins and genes Human genes 0.000 description 146
• 235000018102 proteins Nutrition 0.000 description 136
• 239000002299 complementary DNA Substances 0.000 description 92
• 108020004414 DNA Proteins 0.000 description 65
• 239000013598 vector Substances 0.000 description 63
• 108091028043 Nucleic acid sequence Proteins 0.000 description 50
• 239000012528 membrane Substances 0.000 description 50
• 239000013615 primer Substances 0.000 description 44
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 43
• 210000001519 tissue Anatomy 0.000 description 42
• 108091034117 Oligonucleotide Proteins 0.000 description 36
• 238000002869 basic local alignment search tool Methods 0.000 description 36
• 230000032258 transport Effects 0.000 description 35
• 238000004458 analytical method Methods 0.000 description 33
• 238000003752 polymerase chain reaction Methods 0.000 description 33
• 235000001014 amino acid Nutrition 0.000 description 32
• 208000021642 Muscular disease Diseases 0.000 description 31
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
• 201000009623 Myopathy Diseases 0.000 description 28
• 229940024606 amino acid Drugs 0.000 description 28
• 150000001413 amino acids Chemical class 0.000 description 27
• 238000002493 microarray Methods 0.000 description 25
• 239000013612 plasmid Substances 0.000 description 25
• 238000004422 calculation algorithm Methods 0.000 description 24
• 238000013518 transcription Methods 0.000 description 24
• 230000035897 transcription Effects 0.000 description 24
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 22
• 230000006870 function Effects 0.000 description 21
• 238000003556 assay Methods 0.000 description 19
• 238000005516 engineering process Methods 0.000 description 19
• 230000001105 regulatory effect Effects 0.000 description 19
• 238000012163 sequencing technique Methods 0.000 description 19
• 239000000758 substrate Substances 0.000 description 19
• 230000000875 corresponding effect Effects 0.000 description 18
• 238000000746 purification Methods 0.000 description 18
• 239000003814 drug Substances 0.000 description 17
• 238000006467 substitution reaction Methods 0.000 description 17
• 208000011580 syndromic disease Diseases 0.000 description 17
• 108091026890 Coding region Proteins 0.000 description 16
• 241000700605 Viruses Species 0.000 description 16
• 210000000170 cell membrane Anatomy 0.000 description 16
• 108020001507 fusion proteins Proteins 0.000 description 16
• 102000037865 fusion proteins Human genes 0.000 description 16
• 238000006243 chemical reaction Methods 0.000 description 15
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 15
• 238000000338 in vitro Methods 0.000 description 15
• 238000013519 translation Methods 0.000 description 15
• 230000000692 anti-sense effect Effects 0.000 description 14
• 208000035475 disorder Diseases 0.000 description 14
• 239000000126 substance Substances 0.000 description 14
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 13
• 239000003153 chemical reaction reagent Substances 0.000 description 13
• 238000001514 detection method Methods 0.000 description 13
• 238000003199 nucleic acid amplification method Methods 0.000 description 13
• 206010028980 Neoplasm Diseases 0.000 description 12
• 230000003321 amplification Effects 0.000 description 12
• 239000007850 fluorescent dye Substances 0.000 description 12
• 102000008102 Ankyrins Human genes 0.000 description 11
• 108010049777 Ankyrins Proteins 0.000 description 11
• 241000282412 Homo Species 0.000 description 11
• 108010052285 Membrane Proteins Proteins 0.000 description 11
• 230000001580 bacterial effect Effects 0.000 description 11
• 230000007812 deficiency Effects 0.000 description 11
• 241000894007 species Species 0.000 description 11
• 102000004190 Enzymes Human genes 0.000 description 10
• 108090000790 Enzymes Proteins 0.000 description 10
• 241000124008 Mammalia Species 0.000 description 10
• 108010038807 Oligopeptides Proteins 0.000 description 10
• 102000015636 Oligopeptides Human genes 0.000 description 10
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
• 125000000539 amino acid group Chemical group 0.000 description 10
• 210000000349 chromosome Anatomy 0.000 description 10
• 229940088598 enzyme Drugs 0.000 description 10
• 230000001939 inductive effect Effects 0.000 description 10
• -1 polyethylene Polymers 0.000 description 10
• 108020004635 Complementary DNA Proteins 0.000 description 9
• 102000018697 Membrane Proteins Human genes 0.000 description 9
• 108091093037 Peptide nucleic acid Proteins 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 230000002759 chromosomal effect Effects 0.000 description 9
• 210000000805 cytoplasm Anatomy 0.000 description 9
• 238000001415 gene therapy Methods 0.000 description 9
• 239000005090 green fluorescent protein Substances 0.000 description 9
• 208000015181 infectious disease Diseases 0.000 description 9
• 239000003112 inhibitor Substances 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 108020004999 messenger RNA Proteins 0.000 description 9
• 230000035772 mutation Effects 0.000 description 9
• 230000002265 prevention Effects 0.000 description 9
• 238000000926 separation method Methods 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 230000003612 virological effect Effects 0.000 description 9
• 108020004705 Codon Proteins 0.000 description 8
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 8
• 108700024394 Exon Proteins 0.000 description 8
• 241000700584 Simplexvirus Species 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 210000001124 body fluid Anatomy 0.000 description 8
• 239000010839 body fluid Substances 0.000 description 8
• 238000010367 cloning Methods 0.000 description 8
• 238000010276 construction Methods 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 210000001163 endosome Anatomy 0.000 description 8
• 239000003623 enhancer Substances 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 230000036961 partial effect Effects 0.000 description 8
• 208000033808 peripheral neuropathy Diseases 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• 238000001890 transfection Methods 0.000 description 8
• 241000701161 unidentified adenovirus Species 0.000 description 8
• 238000005406 washing Methods 0.000 description 8
• 108090000994 Catalytic RNA Proteins 0.000 description 7
• 102000053642 Catalytic RNA Human genes 0.000 description 7
• 238000001712 DNA sequencing Methods 0.000 description 7
• 102000005720 Glutathione transferase Human genes 0.000 description 7
• 108010070675 Glutathione transferase Proteins 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 108010026552 Proteome Proteins 0.000 description 7
• 201000011510 cancer Diseases 0.000 description 7
• 238000003745 diagnosis Methods 0.000 description 7
• 210000000688 human artificial chromosome Anatomy 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 238000002372 labelling Methods 0.000 description 7
• 210000004072 lung Anatomy 0.000 description 7
• 230000004048 modification Effects 0.000 description 7
• 238000012986 modification Methods 0.000 description 7
• 210000003463 organelle Anatomy 0.000 description 7
• 229920000642 polymer Polymers 0.000 description 7
• 108091092562 ribozyme Proteins 0.000 description 7
• 230000028327 secretion Effects 0.000 description 7
• 238000012546 transfer Methods 0.000 description 7
• 230000009466 transformation Effects 0.000 description 7
• 230000028973 vesicle-mediated transport Effects 0.000 description 7
• 241000894006 Bacteria Species 0.000 description 6
• 241000196324 Embryophyta Species 0.000 description 6
• 241000725303 Human immunodeficiency virus Species 0.000 description 6
• 208000013016 Hypoglycemia Diseases 0.000 description 6
• 206010061218 Inflammation Diseases 0.000 description 6
• 208000012902 Nervous system disease Diseases 0.000 description 6
• 206010033799 Paralysis Diseases 0.000 description 6
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
• 108010029485 Protein Isoforms Proteins 0.000 description 6
• 102000001708 Protein Isoforms Human genes 0.000 description 6
• 108091034057 RNA (poly(A)) Proteins 0.000 description 6
• 102000000583 SNARE Proteins Human genes 0.000 description 6
• 108010041948 SNARE Proteins Proteins 0.000 description 6
• 108091005764 adaptor proteins Proteins 0.000 description 6
• 102000035181 adaptor proteins Human genes 0.000 description 6
• 230000000890 antigenic effect Effects 0.000 description 6
• 230000001363 autoimmune Effects 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 238000003776 cleavage reaction Methods 0.000 description 6
• 230000001086 cytosolic effect Effects 0.000 description 6
• 201000001981 dermatomyositis Diseases 0.000 description 6
• 239000012153 distilled water Substances 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 206010015037 epilepsy Diseases 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 239000011521 glass Substances 0.000 description 6
• XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 6
• 230000002218 hypoglycaemic effect Effects 0.000 description 6
• 230000028993 immune response Effects 0.000 description 6
• 238000003018 immunoassay Methods 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 238000003780 insertion Methods 0.000 description 6
• 230000037431 insertion Effects 0.000 description 6
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
• 150000002632 lipids Chemical class 0.000 description 6
• 239000002502 liposome Substances 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 206010028417 myasthenia gravis Diseases 0.000 description 6
• 208000005987 polymyositis Diseases 0.000 description 6
• 230000007017 scission Effects 0.000 description 6
• 210000002504 synaptic vesicle Anatomy 0.000 description 6
• 102000003137 synaptotagmin Human genes 0.000 description 6
• 108060008004 synaptotagmin Proteins 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
• 230000002588 toxic effect Effects 0.000 description 6
• 210000003412 trans-golgi network Anatomy 0.000 description 6
• 241001529453 unidentified herpesvirus Species 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 6
• 208000023328 Basedow disease Diseases 0.000 description 5
• 102000053602 DNA Human genes 0.000 description 5
• 102000030782 GTP binding Human genes 0.000 description 5
• 108091000058 GTP-Binding Proteins 0.000 description 5
• 208000015023 Graves' disease Diseases 0.000 description 5
• 206010020772 Hypertension Diseases 0.000 description 5
• 206010029216 Nervousness Diseases 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 5
• 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 5
• 241000700159 Rattus Species 0.000 description 5
• 238000012300 Sequence Analysis Methods 0.000 description 5
• 102000004874 Synaptophysin Human genes 0.000 description 5
• 108090001076 Synaptophysin Proteins 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 239000000427 antigen Substances 0.000 description 5
• 108091007433 antigens Proteins 0.000 description 5
• 102000036639 antigens Human genes 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 230000002255 enzymatic effect Effects 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 230000013595 glycosylation Effects 0.000 description 5
• 238000006206 glycosylation reaction Methods 0.000 description 5
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 201000001119 neuropathy Diseases 0.000 description 5
• 230000007823 neuropathy Effects 0.000 description 5
• 238000004806 packaging method and process Methods 0.000 description 5
• 102000054765 polymorphisms of proteins Human genes 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 239000002987 primer (paints) Substances 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 230000006798 recombination Effects 0.000 description 5
• 238000005215 recombination Methods 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 230000001177 retroviral effect Effects 0.000 description 5
• 150000003384 small molecules Chemical class 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 231100000331 toxic Toxicity 0.000 description 5
• 241000701447 unidentified baculovirus Species 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• 208000030507 AIDS Diseases 0.000 description 4
• 206010001367 Adrenal insufficiency Diseases 0.000 description 4
• 241000710929 Alphavirus Species 0.000 description 4
• 208000024827 Alzheimer disease Diseases 0.000 description 4
• 208000000044 Amnesia Diseases 0.000 description 4
• 208000031091 Amnestic disease Diseases 0.000 description 4
• 206010002198 Anaphylactic reaction Diseases 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• 208000031229 Cardiomyopathies Diseases 0.000 description 4
• 102000005853 Clathrin Human genes 0.000 description 4
• 108010019874 Clathrin Proteins 0.000 description 4
• 108091035707 Consensus sequence Proteins 0.000 description 4
• 239000003155 DNA primer Substances 0.000 description 4
• 206010012289 Dementia Diseases 0.000 description 4
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 4
• 208000014094 Dystonic disease Diseases 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 4
• 208000007223 Gerstmann syndrome Diseases 0.000 description 4
• 206010053185 Glycogen storage disease type II Diseases 0.000 description 4
• 101710154606 Hemagglutinin Proteins 0.000 description 4
• 201000002169 Mitochondrial myopathy Diseases 0.000 description 4
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 4
• 201000002481 Myositis Diseases 0.000 description 4
• 206010068871 Myotonic dystrophy Diseases 0.000 description 4
• 208000025966 Neurological disease Diseases 0.000 description 4
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
• 208000018737 Parkinson disease Diseases 0.000 description 4
• 108010002747 Pfu DNA polymerase Proteins 0.000 description 4
• ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 4
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 4
• 101710176177 Protein A56 Proteins 0.000 description 4
• 201000004681 Psoriasis Diseases 0.000 description 4
• 208000028017 Psychotic disease Diseases 0.000 description 4
• 241000714474 Rous sarcoma virus Species 0.000 description 4
• 102000005890 Spectrin Human genes 0.000 description 4
• 108010019965 Spectrin Proteins 0.000 description 4
• 108091081024 Start codon Proteins 0.000 description 4
• 208000000323 Tourette Syndrome Diseases 0.000 description 4
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
• 230000005856 abnormality Effects 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 208000017515 adrenocortical insufficiency Diseases 0.000 description 4
• 230000006986 amnesia Effects 0.000 description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
• 208000003455 anaphylaxis Diseases 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 238000000137 annealing Methods 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 208000006673 asthma Diseases 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 238000001574 biopsy Methods 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 150000001720 carbohydrates Chemical class 0.000 description 4
• 206010007776 catatonia Diseases 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 229930193282 clathrin Natural products 0.000 description 4
• 238000007877 drug screening Methods 0.000 description 4
• 208000010118 dystonia Diseases 0.000 description 4
• 230000002124 endocrine Effects 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• 201000004502 glycogen storage disease II Diseases 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 239000000185 hemagglutinin Substances 0.000 description 4
• 238000002744 homologous recombination Methods 0.000 description 4
• 230000006801 homologous recombination Effects 0.000 description 4
• 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 4
• 201000008319 inclusion body myositis Diseases 0.000 description 4
• 230000002458 infectious effect Effects 0.000 description 4
• 208000027866 inflammatory disease Diseases 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 239000006166 lysate Substances 0.000 description 4
• 238000013507 mapping Methods 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 201000006417 multiple sclerosis Diseases 0.000 description 4
• 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 210000004940 nucleus Anatomy 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 230000000737 periodic effect Effects 0.000 description 4
• 230000026731 phosphorylation Effects 0.000 description 4
• 238000006366 phosphorylation reaction Methods 0.000 description 4
• 208000020016 psychiatric disease Diseases 0.000 description 4
• 238000003127 radioimmunoassay Methods 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 230000035945 sensitivity Effects 0.000 description 4
• 230000035939 shock Effects 0.000 description 4
• 238000010561 standard procedure Methods 0.000 description 4
• 231100000399 thyrotoxic Toxicity 0.000 description 4
• 230000001897 thyrotoxic effect Effects 0.000 description 4
• 230000005945 translocation Effects 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• 241001430294 unidentified retrovirus Species 0.000 description 4
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 3
• 241000972773 Aulopiformes Species 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 101710132601 Capsid protein Proteins 0.000 description 3
• 108091006146 Channels Proteins 0.000 description 3
• 102000016726 Coat Protein Complex I Human genes 0.000 description 3
• 108010092897 Coat Protein Complex I Proteins 0.000 description 3
• 101710094648 Coat protein Proteins 0.000 description 3
• 102400000739 Corticotropin Human genes 0.000 description 3
• 101800000414 Corticotropin Proteins 0.000 description 3
• 201000003883 Cystic fibrosis Diseases 0.000 description 3
• 241000701022 Cytomegalovirus Species 0.000 description 3
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
• 108010042407 Endonucleases Proteins 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 108091060211 Expressed sequence tag Proteins 0.000 description 3
• 108090000288 Glycoproteins Proteins 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 206010018498 Goitre Diseases 0.000 description 3
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 102000004877 Insulin Human genes 0.000 description 3
• 108090001061 Insulin Proteins 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
• 101710125418 Major capsid protein Proteins 0.000 description 3
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
• 101710141454 Nucleoprotein Proteins 0.000 description 3
• 108700026244 Open Reading Frames Proteins 0.000 description 3
• 208000012868 Overgrowth Diseases 0.000 description 3
• 241000288906 Primates Species 0.000 description 3
• 101710083689 Probable capsid protein Proteins 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 108010005730 R-SNARE Proteins Proteins 0.000 description 3
• 102000005917 R-SNARE Proteins Human genes 0.000 description 3
• 102000018673 SEC Translocation Channels Human genes 0.000 description 3
• 108010091732 SEC Translocation Channels Proteins 0.000 description 3
• 241000710961 Semliki Forest virus Species 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
• 108010006785 Taq Polymerase Proteins 0.000 description 3
• 102100036407 Thioredoxin Human genes 0.000 description 3
• 108020004440 Thymidine kinase Proteins 0.000 description 3
• 241000700618 Vaccinia virus Species 0.000 description 3
• 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 208000026935 allergic disease Diseases 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 230000003115 biocidal effect Effects 0.000 description 3
• 210000002459 blastocyst Anatomy 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 238000007385 chemical modification Methods 0.000 description 3
• 239000003184 complementary RNA Substances 0.000 description 3
• 230000009918 complex formation Effects 0.000 description 3
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
• 229960000258 corticotropin Drugs 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 201000010064 diabetes insipidus Diseases 0.000 description 3
• VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 3
• 230000002526 effect on cardiovascular system Effects 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 230000005284 excitation Effects 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 238000010353 genetic engineering Methods 0.000 description 3
• 208000005594 glucose-galactose malabsorption Diseases 0.000 description 3
• 201000003872 goiter Diseases 0.000 description 3
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 231100000283 hepatitis Toxicity 0.000 description 3
• 201000001421 hyperglycemia Diseases 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 229940125396 insulin Drugs 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 201000005202 lung cancer Diseases 0.000 description 3
• 208000020816 lung neoplasm Diseases 0.000 description 3
• 239000006249 magnetic particle Substances 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 238000004949 mass spectrometry Methods 0.000 description 3
• 230000034217 membrane fusion Effects 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 229960004452 methionine Drugs 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 238000003032 molecular docking Methods 0.000 description 3
• 239000003068 molecular probe Substances 0.000 description 3
• 229930014626 natural product Natural products 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 230000001323 posttranslational effect Effects 0.000 description 3
• 238000001556 precipitation Methods 0.000 description 3
• 230000000644 propagated effect Effects 0.000 description 3
• 230000004952 protein activity Effects 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• 238000011002 quantification Methods 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 108091008146 restriction endonucleases Proteins 0.000 description 3
• 238000010839 reverse transcription Methods 0.000 description 3
• 210000003705 ribosome Anatomy 0.000 description 3
• 235000019515 salmon Nutrition 0.000 description 3
• 238000002864 sequence alignment Methods 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 108060008226 thioredoxin Proteins 0.000 description 3
• 229940113082 thymine Drugs 0.000 description 3
• 238000010361 transduction Methods 0.000 description 3
• 230000026683 transduction Effects 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 210000003956 transport vesicle Anatomy 0.000 description 3
• 230000007332 vesicle formation Effects 0.000 description 3
• 230000009385 viral infection Effects 0.000 description 3
• ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 102000055025 Adenosine deaminases Human genes 0.000 description 2
• 102100034452 Alternative prion protein Human genes 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 208000019901 Anxiety disease Diseases 0.000 description 2
• 206010003591 Ataxia Diseases 0.000 description 2
• 208000004300 Atrophic Gastritis Diseases 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
• 208000020925 Bipolar disease Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 206010049765 Bradyarrhythmia Diseases 0.000 description 2
• 208000004020 Brain Abscess Diseases 0.000 description 2
• 208000014644 Brain disease Diseases 0.000 description 2
• 206010006811 Bursitis Diseases 0.000 description 2
• 102000000584 Calmodulin Human genes 0.000 description 2
• 108010041952 Calmodulin Proteins 0.000 description 2
• 108090000565 Capsid Proteins Proteins 0.000 description 2
• 208000002177 Cataract Diseases 0.000 description 2
• 208000015374 Central core disease Diseases 0.000 description 2
• 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 2
• 102100023321 Ceruloplasmin Human genes 0.000 description 2
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 108020004394 Complementary RNA Proteins 0.000 description 2
• 206010010356 Congenital anomaly Diseases 0.000 description 2
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
• 208000019736 Cranial nerve disease Diseases 0.000 description 2
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 206010011778 Cystinuria Diseases 0.000 description 2
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
• 108010017826 DNA Polymerase I Proteins 0.000 description 2
• 102000004594 DNA Polymerase I Human genes 0.000 description 2
• 206010011891 Deafness neurosensory Diseases 0.000 description 2
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 206010012442 Dermatitis contact Diseases 0.000 description 2
• 208000012239 Developmental disease Diseases 0.000 description 2
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
• 201000010374 Down Syndrome Diseases 0.000 description 2
• 208000027534 Emotional disease Diseases 0.000 description 2
• 206010014561 Emphysema Diseases 0.000 description 2
• 208000032274 Encephalopathy Diseases 0.000 description 2
• 102000004533 Endonucleases Human genes 0.000 description 2
• 241001635598 Enicostema Species 0.000 description 2
• 241000701867 Enterobacteria phage T7 Species 0.000 description 2
• 206010014950 Eosinophilia Diseases 0.000 description 2
• 206010015226 Erythema nodosum Diseases 0.000 description 2
• 206010049466 Erythroblastosis Diseases 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 206010061846 Extradural abscess Diseases 0.000 description 2
• 208000004929 Facial Paralysis Diseases 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
• KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 description 2
• 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
• 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
• 208000003098 Ganglion Cysts Diseases 0.000 description 2
• 208000036495 Gastritis atrophic Diseases 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• 102000053187 Glucuronidase Human genes 0.000 description 2
• 108010060309 Glucuronidase Proteins 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 2
• 208000024869 Goodpasture syndrome Diseases 0.000 description 2
• 201000005569 Gout Diseases 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• 208000035150 Hypercholesterolemia Diseases 0.000 description 2
• 208000002682 Hyperkalemia Diseases 0.000 description 2
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
• 208000010317 Iminoglycinuria Diseases 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• 208000004575 Infectious Arthritis Diseases 0.000 description 2
• 102100034349 Integrase Human genes 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 102000007330 LDL Lipoproteins Human genes 0.000 description 2
• 108010007622 LDL Lipoproteins Proteins 0.000 description 2
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 206010025327 Lymphopenia Diseases 0.000 description 2
• NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 2
• 206010027202 Meningitis bacterial Diseases 0.000 description 2
• 206010027260 Meningitis viral Diseases 0.000 description 2
• 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 2
• 208000012583 Menkes disease Diseases 0.000 description 2
• 208000036626 Mental retardation Diseases 0.000 description 2
• 206010068836 Metabolic myopathy Diseases 0.000 description 2
• 208000019695 Migraine disease Diseases 0.000 description 2
• 208000016285 Movement disease Diseases 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 208000029578 Muscle disease Diseases 0.000 description 2
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
• 208000003926 Myelitis Diseases 0.000 description 2
• 208000009525 Myocarditis Diseases 0.000 description 2
• 208000002033 Myoclonus Diseases 0.000 description 2
• 206010028643 Myopathy endocrine Diseases 0.000 description 2
• 206010028648 Myopathy toxic Diseases 0.000 description 2
• 208000023137 Myotoxicity Diseases 0.000 description 2
• 108010081735 N-Ethylmaleimide-Sensitive Proteins Proteins 0.000 description 2
• 208000009905 Neurofibromatoses Diseases 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 206010033645 Pancreatitis Diseases 0.000 description 2
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 108091000054 Prion Proteins 0.000 description 2
• 208000024777 Prion disease Diseases 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 208000001431 Psychomotor Agitation Diseases 0.000 description 2
• 208000006396 Pulmonary artery stenosis Diseases 0.000 description 2
• 206010037651 Pyometra Diseases 0.000 description 2
• 108010010469 Qa-SNARE Proteins Proteins 0.000 description 2
• 108020004518 RNA Probes Proteins 0.000 description 2
• 239000003391 RNA probe Substances 0.000 description 2
• 102000011070 Rab3 Human genes 0.000 description 2
• 108050001276 Rab3 Proteins 0.000 description 2
• 206010037779 Radiculopathy Diseases 0.000 description 2
• 241000700157 Rattus norvegicus Species 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 206010038743 Restlessness Diseases 0.000 description 2
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
• 108091028664 Ribonucleotide Proteins 0.000 description 2
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 208000036752 Schizophrenia, paranoid type Diseases 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 108010051611 Signal Recognition Particle Proteins 0.000 description 2
• 102000013598 Signal recognition particle Human genes 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
• 241000710960 Sindbis virus Species 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 102000006384 Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins Human genes 0.000 description 2
• 108010019040 Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins Proteins 0.000 description 2
• 208000029033 Spinal Cord disease Diseases 0.000 description 2
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
• 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 108091027544 Subgenomic mRNA Proteins 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 208000005400 Synovial Cyst Diseases 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 102100037667 TNFAIP3-interacting protein 1 Human genes 0.000 description 2
• 101710149776 TNFAIP3-interacting protein 1 Proteins 0.000 description 2
• 206010049447 Tachyarrhythmia Diseases 0.000 description 2
• 208000001871 Tachycardia Diseases 0.000 description 2
• 108091036066 Three prime untranslated region Proteins 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 241000723873 Tobacco mosaic virus Species 0.000 description 2
• 108700009124 Transcription Initiation Site Proteins 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 108091023045 Untranslated Region Proteins 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 2
• GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
• 108010004977 Vasopressins Proteins 0.000 description 2
• 102000002852 Vasopressins Human genes 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 102100035054 Vesicle-fusing ATPase Human genes 0.000 description 2
• 108010067390 Viral Proteins Proteins 0.000 description 2
• 201000011032 Werner Syndrome Diseases 0.000 description 2
• 208000018839 Wilson disease Diseases 0.000 description 2
• 201000004525 Zellweger Syndrome Diseases 0.000 description 2
• 208000036813 Zellweger spectrum disease Diseases 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 208000017733 acquired polycythemia vera Diseases 0.000 description 2
• 208000009621 actinic keratosis Diseases 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 230000001919 adrenal effect Effects 0.000 description 2
• 210000004100 adrenal gland Anatomy 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 230000036783 anaphylactic response Effects 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 229940125644 antibody drug Drugs 0.000 description 2
• 239000000074 antisense oligonucleotide Substances 0.000 description 2
• 238000012230 antisense oligonucleotides Methods 0.000 description 2
• 230000036506 anxiety Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
• 238000000149 argon plasma sintering Methods 0.000 description 2
• 238000003491 array Methods 0.000 description 2
• 206010003119 arrhythmia Diseases 0.000 description 2
• 230000006793 arrhythmia Effects 0.000 description 2
• 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 210000003403 autonomic nervous system Anatomy 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 201000009904 bacterial meningitis Diseases 0.000 description 2
• 208000018300 basal ganglia disease Diseases 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000000975 bioactive effect Effects 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 230000008236 biological pathway Effects 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 210000000625 blastula Anatomy 0.000 description 2
• 239000002981 blocking agent Substances 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 208000006218 bradycardia Diseases 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 206010006451 bronchitis Diseases 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 238000010804 cDNA synthesis Methods 0.000 description 2
• 238000005251 capillar electrophoresis Methods 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 201000007303 central core myopathy Diseases 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 206010008129 cerebral palsy Diseases 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 229920001429 chelating resin Polymers 0.000 description 2
• 239000005081 chemiluminescent agent Substances 0.000 description 2
• 201000001352 cholecystitis Diseases 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000003200 chromosome mapping Methods 0.000 description 2
• 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 208000019425 cirrhosis of liver Diseases 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 238000004590 computer program Methods 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 208000010247 contact dermatitis Diseases 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 210000004292 cytoskeleton Anatomy 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 208000016097 disease of metabolism Diseases 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 238000000295 emission spectrum Methods 0.000 description 2
• 230000012202 endocytosis Effects 0.000 description 2
• 108700004025 env Genes Proteins 0.000 description 2
• 201000000165 epidural abscess Diseases 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 230000028023 exocytosis Effects 0.000 description 2
• 208000015700 familial long QT syndrome Diseases 0.000 description 2
• 201000006061 fatal familial insomnia Diseases 0.000 description 2
• 206010016629 fibroma Diseases 0.000 description 2
• 206010049444 fibromatosis Diseases 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 210000000232 gallbladder Anatomy 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 238000001476 gene delivery Methods 0.000 description 2
• 102000054767 gene variant Human genes 0.000 description 2
• 208000016361 genetic disease Diseases 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 210000004907 gland Anatomy 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 238000001631 haemodialysis Methods 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 108060003552 hemocyanin Proteins 0.000 description 2
• 230000000322 hemodialysis Effects 0.000 description 2
• 201000003636 hereditary ataxia Diseases 0.000 description 2
• 208000021760 high fever Diseases 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 230000036737 immune function Effects 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 208000000509 infertility Diseases 0.000 description 2
• 230000036512 infertility Effects 0.000 description 2
• 231100000535 infertility Toxicity 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
• 206010023497 kuru Diseases 0.000 description 2
• 208000006443 lactic acidosis Diseases 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 208000036546 leukodystrophy Diseases 0.000 description 2
• 230000029226 lipidation Effects 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 230000000527 lymphocytic effect Effects 0.000 description 2
• 231100001023 lymphopenia Toxicity 0.000 description 2
• 210000003712 lysosome Anatomy 0.000 description 2
• 230000001868 lysosomic effect Effects 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 230000007721 medicinal effect Effects 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
• 206010027599 migraine Diseases 0.000 description 2
• 238000000329 molecular dynamics simulation Methods 0.000 description 2
• 230000036651 mood Effects 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 230000036457 multidrug resistance Effects 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 201000006938 muscular dystrophy Diseases 0.000 description 2
• 206010028537 myelofibrosis Diseases 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 230000002107 myocardial effect Effects 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 210000003739 neck Anatomy 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 201000004931 neurofibromatosis Diseases 0.000 description 2
• 230000002232 neuromuscular Effects 0.000 description 2
• 208000018360 neuromuscular disease Diseases 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 206010030875 ophthalmoplegia Diseases 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 208000002851 paranoid schizophrenia Diseases 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• 230000003071 parasitic effect Effects 0.000 description 2
• 230000000849 parathyroid Effects 0.000 description 2
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
• 210000003899 penis Anatomy 0.000 description 2
• 230000002974 pharmacogenomic effect Effects 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 208000037244 polycythemia vera Diseases 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 238000007639 printing Methods 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• 201000002765 pyometritis Diseases 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 206010061928 radiculitis Diseases 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 230000002207 retinal effect Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 239000002336 ribonucleotide Substances 0.000 description 2
• 125000002652 ribonucleotide group Chemical group 0.000 description 2
• 210000003079 salivary gland Anatomy 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 230000000698 schizophrenic effect Effects 0.000 description 2
• 230000001932 seasonal effect Effects 0.000 description 2
• 238000005204 segregation Methods 0.000 description 2
• 231100000879 sensorineural hearing loss Toxicity 0.000 description 2
• 208000023573 sensorineural hearing loss disease Diseases 0.000 description 2
• 201000001223 septic arthritis Diseases 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 208000007056 sickle cell anemia Diseases 0.000 description 2
• 239000010703 silicon Substances 0.000 description 2
• 229910052710 silicon Inorganic materials 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 208000001608 teratocarcinoma Diseases 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 206010043554 thrombocytopenia Diseases 0.000 description 2
• 201000005060 thrombophlebitis Diseases 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 206010043778 thyroiditis Diseases 0.000 description 2
• 230000002110 toxicologic effect Effects 0.000 description 2
• 231100000027 toxicology Toxicity 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 208000020049 trigeminal nerve disease Diseases 0.000 description 2
• 208000009999 tuberous sclerosis Diseases 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 229940035893 uracil Drugs 0.000 description 2
• 210000003932 urinary bladder Anatomy 0.000 description 2
• 206010046766 uterine cancer Diseases 0.000 description 2
• 229960003726 vasopressin Drugs 0.000 description 2
• 201000010044 viral meningitis Diseases 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 235000012431 wafers Nutrition 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
• ZPZDIFSPRVHGIF-UHFFFAOYSA-N 3-aminopropylsilicon Chemical compound NCCC[Si] ZPZDIFSPRVHGIF-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• 102000016954 ADP-Ribosylation Factors Human genes 0.000 description 1
• 108010053971 ADP-Ribosylation Factors Proteins 0.000 description 1
• 101150018624 ARF6 gene Proteins 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
• 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108010025188 Alcohol oxidase Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 108091006515 Anion channels Proteins 0.000 description 1
• 102000037829 Anion channels Human genes 0.000 description 1
• 108090000672 Annexin A5 Proteins 0.000 description 1
• 102000004121 Annexin A5 Human genes 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 101000933074 Arabidopsis thaliana Protein C2-DOMAIN ABA-RELATED 4 Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
• OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical compound OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 102400000967 Bradykinin Human genes 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 102000002110 C2 domains Human genes 0.000 description 1
• 108050009459 C2 domains Proteins 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 108010041397 CD4 Antigens Proteins 0.000 description 1
• 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 1
• 101100152433 Caenorhabditis elegans tat-1 gene Proteins 0.000 description 1
• 102000055006 Calcitonin Human genes 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
• 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 239000005496 Chlorsulfuron Substances 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 102100022641 Coagulation factor IX Human genes 0.000 description 1
• 102000057710 Coatomer Human genes 0.000 description 1
• 101710112843 Coatomer subunit zeta Proteins 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 102000034534 Cotransporters Human genes 0.000 description 1
• 108020003264 Cotransporters Proteins 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000192700 Cyanobacteria Species 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 238000000018 DNA microarray Methods 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 101100379471 Drosophila melanogaster Arf51F gene Proteins 0.000 description 1
• 102100021238 Dynamin-2 Human genes 0.000 description 1
• 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
• UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 101710091045 Envelope protein Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 108010076282 Factor IX Proteins 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 1
• 241000711950 Filoviridae Species 0.000 description 1
• 108010058643 Fungal Proteins Proteins 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000009292 Hemophilia A Diseases 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
• 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101001104083 Homo sapiens Rabphilin-3A Proteins 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
• 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
• 101150027427 ICP4 gene Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000003746 Insulin Receptor Human genes 0.000 description 1
• 108010001127 Insulin Receptor Proteins 0.000 description 1
• 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 108010025815 Kanamycin Kinase Proteins 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 108700005090 Lethal Genes Proteins 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 239000000232 Lipid Bilayer Substances 0.000 description 1
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
• 241000713869 Moloney murine leukemia virus Species 0.000 description 1
• 108700005084 Multigene Family Proteins 0.000 description 1
• 102000002069 Munc18 Proteins Human genes 0.000 description 1
• 108010001212 Munc18 Proteins Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101100042676 Mus musculus Skap2 gene Proteins 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 241001028048 Nicola Species 0.000 description 1
• 108091093105 Nuclear DNA Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 238000009004 PCR Kit Methods 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108090000445 Parathyroid hormone Proteins 0.000 description 1
• 241000237988 Patellidae Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000015731 Peptide Hormones Human genes 0.000 description 1
• 108010038988 Peptide Hormones Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 101710182846 Polyhedrin Proteins 0.000 description 1
• 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
• 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
• 241000881705 Porcine endogenous retrovirus Species 0.000 description 1
• 101710128385 Probable coatomer subunit zeta Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101710192141 Protein Nef Proteins 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 101710188315 Protein X Proteins 0.000 description 1
• 238000010802 RNA extraction kit Methods 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 102100040040 Rabphilin-3A Human genes 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
• 241000242677 Schistosoma japonicum Species 0.000 description 1
• 241000235346 Schizosaccharomyces Species 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 239000012506 Sephacryl® Substances 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 101710140501 Sulfate adenylyltransferase subunit 2 1 Proteins 0.000 description 1
• 101710173681 Sulfate adenylyltransferase subunit 2 2 Proteins 0.000 description 1
• 102100030100 Sulfate anion transporter 1 Human genes 0.000 description 1
• 101710144481 Sulfate anion transporter 1 Proteins 0.000 description 1
• 102100028522 Synaptophysin-like protein 2 Human genes 0.000 description 1
• 101710169339 Synaptophysin-like protein 2 Proteins 0.000 description 1
• 102000000639 Synaptophysin/synaptoporin Human genes 0.000 description 1
• 108050008093 Synaptophysin/synaptoporin Proteins 0.000 description 1
• 102100030552 Synaptosomal-associated protein 25 Human genes 0.000 description 1
• 102100035002 Synaptotagmin-like protein 4 Human genes 0.000 description 1
• 101710156031 Synaptotagmin-like protein 4 Proteins 0.000 description 1
• 102000050389 Syntaxin Human genes 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 208000002903 Thalassemia Diseases 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 102000009843 Thyroglobulin Human genes 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
• 102000011923 Thyrotropin Human genes 0.000 description 1
• 108010061174 Thyrotropin Proteins 0.000 description 1
• 241000209140 Triticum Species 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 108020000999 Viral RNA Proteins 0.000 description 1
• IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 210000001943 adrenal medulla Anatomy 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 238000011256 aggressive treatment Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 239000004410 anthocyanin Substances 0.000 description 1
• 229930002877 anthocyanin Natural products 0.000 description 1
• 235000010208 anthocyanin Nutrition 0.000 description 1
• 150000004636 anthocyanins Chemical class 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 101150098681 arf4 gene Proteins 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 229950004398 broxuridine Drugs 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 230000009460 calcium influx Effects 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
• 229960003669 carbenicillin Drugs 0.000 description 1
• 230000021523 carboxylation Effects 0.000 description 1
• 238000006473 carboxylation reaction Methods 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 210000002314 coated vesicle Anatomy 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 230000001427 coherent effect Effects 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000006059 cover glass Substances 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 238000009402 cross-breeding Methods 0.000 description 1
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000005220 cytoplasmic tail Anatomy 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 238000003795 desorption Methods 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical group C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• BTWUORFYKAZQHW-UHFFFAOYSA-L disodium;2-hydroxy-3-[4-[4-[(2-hydroxy-3-sulfonatopropyl)amino]-3-methylphenyl]-2-methylanilino]propane-1-sulfonate Chemical compound [Na+].[Na+].C1=C(NCC(O)CS([O-])(=O)=O)C(C)=CC(C=2C=C(C)C(NCC(O)CS([O-])(=O)=O)=CC=2)=C1 BTWUORFYKAZQHW-UHFFFAOYSA-L 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000007878 drug screening assay Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
• 210000001705 ectoderm cell Anatomy 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 210000004039 endoderm cell Anatomy 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000005183 environmental health Effects 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 210000000267 erythroid cell Anatomy 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• 235000020774 essential nutrients Nutrition 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 210000003499 exocrine gland Anatomy 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 229960004222 factor ix Drugs 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000001752 female genitalia Anatomy 0.000 description 1
• 230000004720 fertilization Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 230000009969 flowable effect Effects 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000018578 heart valve disease Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 208000009601 hereditary spherocytosis Diseases 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 238000012203 high throughput assay Methods 0.000 description 1
• 101150113423 hisD gene Proteins 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 210000003917 human chromosome Anatomy 0.000 description 1
• 244000052637 human pathogen Species 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 238000007641 inkjet printing Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 201000009019 intestinal benign neoplasm Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 210000004020 intracellular membrane Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 238000007852 inverse PCR Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical group [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 108010054155 lysyllysine Proteins 0.000 description 1
• 101710130522 mRNA export factor Proteins 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 210000000260 male genitalia Anatomy 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000028161 membrane depolarization Effects 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 210000001704 mesoblast Anatomy 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 229960003248 mifepristone Drugs 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 229940125645 monoclonal antibody drug Drugs 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 210000002346 musculoskeletal system Anatomy 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 239000006225 natural substrate Substances 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 229960002748 norepinephrine Drugs 0.000 description 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 108010082527 phosphinothricin N-acetyltransferase Proteins 0.000 description 1
• 238000000206 photolithography Methods 0.000 description 1
• 238000005375 photometry Methods 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000003518 presynaptic effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000009993 protective function Effects 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 238000002331 protein detection Methods 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 230000018883 protein targeting Effects 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 244000000040 protozoan parasite Species 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000037425 regulation of transcription Effects 0.000 description 1
• 230000009712 regulation of translation Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 230000007441 retrograde transport Effects 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 210000004767 rumen Anatomy 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 101150055530 sat gene Proteins 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 238000010187 selection method Methods 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 210000000697 sensory organ Anatomy 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 108040000979 soluble NSF attachment protein activity proteins Proteins 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000013179 statistical model Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000001548 stomatognathic system Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 238000005382 thermal cycling Methods 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 229960002175 thyroglobulin Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 239000005495 thyroid hormone Substances 0.000 description 1
• 229940036555 thyroid hormone Drugs 0.000 description 1
• 229960000874 thyrotropin Drugs 0.000 description 1
• 230000001748 thyrotropin Effects 0.000 description 1
• 238000012090 tissue culture technique Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000167 toxic agent Toxicity 0.000 description 1
• 230000008280 toxic mechanism Effects 0.000 description 1
• 231100000563 toxic property Toxicity 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• 108091008023 transcriptional regulators Proteins 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 238000011426 transformation method Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 230000010415 tropism Effects 0.000 description 1
• 101150081616 trpB gene Proteins 0.000 description 1
• 101150111232 trpB-1 gene Proteins 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
• 230000009452 underexpressoin Effects 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
• QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1